SPPI Stock News 7.47 05/13/2014 15:27:38 Spectrum Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Spectrum Pharmaceuticals (SPPI) 7.47 $SPPI

Mallinckrodt Earnings Beat, Shares Dip on Low Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 10:30AM CDT
Mallinckrodt's (MNK) shares have been moving downwards following the company's revenue miss.

Technical Report on Top Gainers -- Research on Spectrum Pharma, Polypore Intl., Tuesday Morning, and Universal Display
PR Newswire - Mon May 12, 10:30AM CDT
The US markets saw a positive sentiment on Friday, May 09, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session 0.20% higher at 16,583.34, and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. During the session gains in the Consumer Discretionary, Health Care and Consumer Staples sectors positively impacted the broader market, while some retraction came in from Materials, Financials, and Energy sectors. A number of stocks saw large movements, including Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Polypore International Inc. (NYSE: PPO), Tuesday Morning Corporation (NASDAQ: TUES) and Universal Display Corporation (NASDAQ: OLED). Free technical research on SPPI, PPO, TUES and OLED can be downloaded upon signing up at:

Shares Continue to fall on Emergent BioSolutions' Wider Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 9:10AM CDT
Shares of Emergent BioSolutions (EBS) have been on the way down since it reported wider first quarter 2014 loss.

PharmAthene (PIP) Catches Eye: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:46AM CDT
PharmAthene (PIP) was a big mover last session, as the company saw its shares rise over 6% on the day.

Dendreon Falls on Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:40AM CDT
Dendreon (DNDN) reported first-quarter 2014 lossof 18 cents per share, narrower than the Zacks Consensus Estimate of a loss of 30 cents.

Spectrum Pharma Up on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:00AM CDT
Spectrum Pharma's (SPPI) first quarter 2014 earnings of a penny per share were flat year over year.

Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas on May 13th
Business Wire - Fri May 09, 6:00AM CDT
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Bank of America Merrill Lynch 2014 Health Care Conference being held at The Encore at Wynn in Las Vegas, Nevada. The Company presentation is on Tuesday, May 13, 2014, at 2:20 PM PT.

Infinity Pharma Down on Wider-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 4:20PM CDT
Infinity Pharma (INFI) reported a loss of 87 cents per share in the first quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 80 cents.

Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2014
Business Wire - Thu May 08, 3:01PM CDT
--Non-GAAP EPS was $0.01, and GAAP EPS was ($0.44).

ARIAD's Q1 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 11:00AM CDT
ARIAD Pharmaceuticals Inc. (ARIA) reported narrower-than-expected loss in the first quarter of 2014.

Wider-than-Expected Q1 Loss at Nektar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 10:20AM CDT
Nektar (NKTR) reported a loss of 37 cents per share in the first quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 35 cents.

Hyperphosphatemia - Pipeline Review, H1 2014: 8 Companies and 11 Drug Profiles
M2 - Thu May 08, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cg8bjr/hyperphosphatemia) has announced the addition of the "Hyperphosphatemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hyperphosphatemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hyperphosphatemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hyperphosphatemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - AstraZeneca PLC - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - Toray Industries, Inc. - Spectrum Pharmaceuticals, Inc. - Vifor Pharma AG - Medice Arzneimittel Putter GmbH & Co. KG Drug Profiles: - colestilan chloride - sucroferric oxyhydroxide - niacinamide - SPI-014 - tenapanor - colestilan chloride - PT-20 - ASP-3325 - Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia - JPH-101 - TRK-390 For more information visit http://www.researchandmarkets.com/research/cg...osphatemia

Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube

Brain Metastasis - Pipeline Review, H1 2014: 14 Company and 19 Drug Profiles
M2 - Wed May 07, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7mxglb/brain_metastasis) has announced the addition of the "Brain Metastasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Metastasis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - AbbVie Inc. - AngioChem Inc. - Cell Therapeutics, Inc. - Diffusion Pharmaceuticals LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Nanobiotix - Nerviano Medical Sciences S.r.l. - Philogen S.p.A. - Puma Biotechnology, Inc. - Sanofi - Spectrum Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - biOasis Technologies Inc. Drug Profiles: - neratinib - paclitaxel poliglumex - lucanthone hydrochloride - ANG-1005 - lapatinib ditosylate - veliparib - dabrafenib trametinib - dabrafenib - cabazitaxel - trastuzumab - radretumab - Trans Sodium Crocetinate - PB-357 - Therapeutic p53 Gene Agent - TAK-285 - BT-2111 - ANG-4043 - NBTX-IV - NMSE-973 For more information visit http://www.researchandmarkets.com/research/7m..._metastasi

Is A Short Squeeze Ahead for Spectrum Pharmaceuticals (SPPI)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 8:19AM CDT
Is A Short Squeeze Ahead for Spectrum Pharmaceuticals (SPPI)?

13.7% Return Seen to Date on SmarTrend Spectrum Pharmaceuticals Call (SPPI)
Comtex SmarTrend(R) - Tue May 06, 9:29AM CDT
SmarTrend identified a Downtrend for Spectrum Pharmaceuticals (NASDAQ:SPPI) on February 4th, 2014 at $8.18. In approximately 3 months, Spectrum Pharmaceuticals has returned 13.69% as of today's recent price of $7.06.

Clinical Winners and Losers: Spectrum Pharmaceuticals and Cytokinetics
Cory Renauer, The Motley Fool - Motley Fool - Fri May 02, 8:30AM CDT
Clinical trial highlights took a back seat last week to the stream of blockbuster deals in the health care sector. Still, there was a big winner and a big loser -- even if they flew relatively under the radar.  Spectrum Pharmaceuticals  was, in my...

Spectrum Pharmaceuticals Announces First Quarter 2014 Financial Results Teleconference and Webcast
Business Wire - Thu May 01, 6:02AM CDT
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the first quarter 2014 financial results, provide an update on the Company's business, and discuss expectations for the future.

Metastatic Uveal Melanoma Clinical Trials Review - H1 2014 Edition
M2 - Wed Apr 30, 11:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btn5xl/metastatic_uveal) has announced the addition of the "Metastatic Uveal Melanoma Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Uveal Melanoma Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Uveal Melanoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Uveal Melanoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Uveal Melanoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Novartis AG - AstraZeneca PLC - GlaxoSmithKline plc - Spectrum Pharmaceuticals, Inc. - National Cancer Institute - The Clatterbridge Cancer Centre NHS Foundation Trust - The University of Texas M. D. Anderson Cancer Center - Alberta Health Services - Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital - Memorial Sloan Kettering Cancer Center - Ludwig-Maximilians-Universitat Munich - University Hospital, Essen - Barnes Retina Institute - University of California, Los Angeles For more information visit http://www.researchandmarkets.com/research/bt...atic_uveal

Global Refractory Leukemia Global Clinical Trials Report 2014 - Data for the Top Companies/Institutions
M2 - Tue Apr 29, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szjj8l/refractory) has announced the addition of the "Refractory Leukemia Global Clinical Trials Review, H1, 2014" report to their offering. Refractory Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Refractory Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Leukemia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Refractory Leukemia Therapeutics Clinical Trials - Sanofi - Otsuka Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Spectrum Pharmaceuticals, Inc. - Merck & Co., Inc. - Johnson & Johnson - Bristol-Myers Squibb Company - BioCryst Pharmaceuticals, Inc. - AEterna Zentaris Inc. - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Sidney Kimmel Comprehensive Cancer Center - Fred Hutchinson Cancer Research Center - National Institutes of Health Clinical Center - Seattle Children's Hospital, Research and Foundation - Children's Oncology Group - Case Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/szjj8l/refractory
Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 454

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 283

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 493

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 66

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 77

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Ventas to Showcase Investment Strategy at Real Estate Conference

Updated Category News Views 44

Ventas Engages Investors at Upcoming Conference Ventas, Inc. (NYSE: VTR) is gearing up to take part in significant investor meetings at the BofA Securities 2024 Global Real Estate Conference. This event presents a valuable chance for the company to connect with investors and share insights about its strategic direction and business model. Event Details and Participation...

Continue Reading
BioLineRx Explores Synergy in Ovarian Cancer Treatment

Updated Category News Views 151

New Hope on the Ovarian Cancer Front Every so often, something comes along and makes you stop and think—could this be the game-changer in the making? Well, what BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS just dropped at the ESMO 2026 feels a bit like that silver lining for folks fighting the uphill battle against homologous recombination (HR)-proficient ovarian...

Continue Reading
Analyst Ratings Show Confidence in Datadog and Others

Updated Category News Views 80

Recent Upgrades by Top Analysts Leading financial analysts from Wall Street have adjusted their outlooks on several prominent companies, reflecting a more optimistic market sentiment. Upgrades often signify increased confidence in a company's performance and present potential investment opportunities for savvy investors. Here, we delve into some of the standout upgrades...

Continue Reading
Unpacking the Increased Short Interest in Ventas (NYSE: VTR)

Updated Category News Views 77

Understanding Ventas's Short Interest Surge Ventas recently recorded an uptick in its short percent of float, which now stands at 25.59% since the last report. This notable development means that 9.80 million shares are currently sold short, translating to 3.19% of all regular shares available for trading. Given the trading volume, it would take traders approximately 3.33...

Continue Reading
Precigen's PAPZIMEOS: 7-Year Exclusivity & Long-Term Success

Updated Category News Views 54

Precigen's Game-Changer: PAPZIMEOS Secures Seven-Year Exclusivity Here's how you carve out a solid niche in the biotech world: deliver some killer results and snag yourself seven years in the driver’s seat. That's exactly what Precigen (NASDAQ: PGEN) has done with their PAPZIMEOS therapy, which got the stamp of approval from the FDA as the first exclusive treatment for...

Continue Reading